Patents by Inventor Mario Vallejo
Mario Vallejo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8672123Abstract: A baby bottle comprised of an upper assembly, a lower assembly and a baffle assembly. The upper assembly is adapted to contain separately a wet ingredient and a lower assembly is adapted to contain a dry ingredient. The baffle assembly includes an integral plug and aperture that rotates relative to the upper assembly so that the upper assembly is selectively in fluid communication with lower assembly to mix the wet and dry ingredients.Type: GrantFiled: January 8, 2013Date of Patent: March 18, 2014Inventors: Mario Vallejo, Juliana High-Vallejo
-
Patent number: 8110399Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 22, 2006Date of Patent: February 7, 2012Assignee: The General Hospital CorporationInventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech, Anna Louise Nolan, Andreas Lechner
-
Patent number: 7544510Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: April 24, 2006Date of Patent: June 9, 2009Assignee: The General Hospital CorporationInventors: Joel F. Habener, Elizabeth J. Abraham, Henryk Zulewski, Melissa K. Thomas, Mario Vallejo
-
Patent number: 7537756Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 19, 2005Date of Patent: May 26, 2009Assignee: The General Hospital CorporationInventors: Joel E. Habener, Hendrik Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 7438902Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: November 9, 2004Date of Patent: October 21, 2008Assignee: The General Hospital CorporationInventors: Joel E. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Publication number: 20070128176Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 22, 2006Publication date: June 7, 2007Inventors: Joel Habener, Henryk Zulewski, Melissa Thomas, Elizabeth Abraham, Mario Vallejo, Colin Leech, Anna Nolan, Andreas Lechner
-
Publication number: 20070071730Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: April 24, 2006Publication date: March 29, 2007Inventors: Joel Habener, Henryk Zulewski, Elizabeth Abraham, Melissa Thomas, Mario Vallejo
-
Publication number: 20060062769Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 19, 2005Publication date: March 23, 2006Inventors: Joel Habener, Hendrik Zulewski, Elizabeth Abraham, Mario Vallejo, Denise Faustman, Melissa Thomas
-
Publication number: 20050244386Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: November 9, 2004Publication date: November 3, 2005Inventors: Joel Habener, Henryk Zulewski, Elizabeth Abraham, Mario Vallejo, Denise Faustman, Melissa Thomas
-
Patent number: 6923959Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 2, 2002Date of Patent: August 2, 2005Assignee: The General Hospital CorporationInventors: Joel F. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 6866843Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: December 6, 2000Date of Patent: March 15, 2005Assignee: Viacell, Inc.Inventors: Joel F. Habener, Henryk Zulewski, Elizabeth Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Publication number: 20030082155Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: April 11, 2002Publication date: May 1, 2003Inventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech, Anna Louise Nolan, Andreas Lechner
-
Publication number: 20030031657Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 2, 2002Publication date: February 13, 2003Applicant: Massachusetts General HospitalInventors: Joel F. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Publication number: 20020164307Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and GLP-1 receptor have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby stem cells which express one or both of nestin and GLP-1R can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed.Type: ApplicationFiled: September 26, 2001Publication date: November 7, 2002Inventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech
-
Publication number: 20010046489Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: December 6, 2000Publication date: November 29, 2001Inventors: Joel E. Habener, Henryk Zulewski, Elizabeth J. Abraham, Melissa K. Thomas, Mario Vallejo